Our senior market strategist explains which ETFs offer exposure to high-powered biotech growth, without T. Rex-sized risk.
Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?
These two companies fit the type of transformative growth story Cathie Wood seeks out.
This dip in Illumina’s stock could be an attractive opportunity for long-term growth investors.
/CNW/ - BMO Investments Inc. ("BMOII") today announced the final net asset values for the ETF Series of each of BMO ARK Genomic Revolution Fund (Cboe Canada:...
The popular investor poured $366.2 million in the company’s shares to carry out her latest purchase.
Wall Street was upbeat last week, with the S&P 500 adding 1.5%, the Dow Jones gaining about 0.6% and the Nasdaq surging 2.6%. Last week witnessed the release of hot January inflation data. The Consumer...
The company has gained a lot of attention since launching an AI-enabled personal health app last month.
The stock is one of the renowned investor’s top holdings.
The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.